Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...
FierceBiotech4d
Innate Pharma antibody pits natural killer cells against cancerous B cells in mice and monkeys
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...
Kaleido Scope39m
Study reveals the disruption of interaction between proteins CD2:CD58 is a potential new treatment option for people with hidradenitis suppurativa
CD2 through its interaction with the cell surface protein, CD58, has critical functions for the activation of T cells and ...
The American Journal of Managed Care13d
KIR2DS2+ NK Cells Show Potential in HCC and Leukemia Treatment
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
Armed robbery in Revesby4d
Dana-Farber Launches Trial for Memory NK Cells
Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...
Too Old to Operate1d
Inhibition of Cbl-b restores effector functions of human intratumoral NK cells.
T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...
Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...